Mirrors of Medicine library
In the spotlight
Clinical case discussion on mRCC
Moderators: Philippe Barthélémy, Bernadett Szabados
Case presenter: Petros Grivas
Panel: Ignacio Duran, Lisa Pickering, Manuela Schmidinger
Petros Grivas presents a case with favourable-risk mRCC. Prior to the discussion the audience votes for their preferred treatment option. The panel has an in-depth discussion on the case. Does this change the opinion of the audience (and that of you)?
Clinical case discussion on mHSPC
Experts: Maria De Santis, Géraldine Pignot, Gunhild von Amsberg
The experts discuss how they would treat this patient who has low-volume PCa on conventional imaging, but high-volume disease on PSMA-PET/CT
Update lecture on first-line treatment for advanced UCa
Moderators: Dora Niedersüß-Beke
Presenter: Gunhild von Amsberg
Gunhild von Amsberg presented at BLADDR 2024 how to individualise the selection of the first-line treatment for advanced UCa based on efficacy, safety, patient characteristics and QoL
Lecture and case discussion on mHSPC
Case presenter: Daan De Maeseneer
Presenter: Gero Kramer
Panel: Elena Castro, Aurelius Omlin, Fabio Turco, Ursula Vogl
A case of a 68-year-old man with mHSPC and comorbidities typical for his age is presented. The audience votes on their preferred treatment option, after which Gero Kramer reviews the latest evidence on managing synchronous mHSPC. The panel discusses how this impacts the clinical case, followed by a re-vote of the audience.
Lecture and case discussion: MIBC congress highlights from ESMO
Moderators: Petros Grivas
Presenter: Maria De Santis
Maria De Santis summarised at BLADDR 2024 the latest data on adjuvant, neoadjuvant and perioperative concepts for MIBC from clinical trials shared at ESMO. She translates this knowledge into clinical practice with a clinical case!
Lecture and clinical case discussion on CRPC
Case presenter: Daan De Maeseneer
Presenter: Elena Castro
Panel: Amarnath Challapalli, Rob Jones, Gero Kramer, Daniele Raggi
Presentation of a patient with mCRPC and a CDK12 mutation. The audience selects their preferred treatment option, followed by a presentation from Elena Castro in which she discusses whether PARP inhibition is the way to go in all CRPC patients. The panel discusses the impact of prior therapies and the role of different mutation types in guiding the management of these patients. Did this discussion change your opinion and that of the audience?
